Follow-on Offering

Follow-on Offering


Baird served as a co-manager in this offering.


Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) (“Optimer” or the “Company”) recently completed the public offering of 6,900,000 shares of its common stock at $11.25 per share, reflecting gross proceeds to the company of $77,625,000. The Company anticipates using the net proceeds from this transaction to prepare for the potential commercial launch of fidaxomicin in the United States, if approved, as well as for research and development of its pipeline of drug candidates, potential in-licenses or acquisitions, working capital and other general corporate purposes.

Optimer is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. The Company has two anti-infective product candidates in development, fidaxomicin and Pruvel™ (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (“CDI”). The FDA granted the Company’s request for six-month Priority Review of the New Drug Application (“NDA”) for fidaxomicin, and has assigned a Prescription Drug User Fee Act (“PDUFA”) goal date of May 30, 2011. The Company also filed a Marketing Authorization Application (“MAA”) with the European Medicines Agency (“EMA”) for fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea.

For additional information about this transaction, please contact:

Frank Stokes 704-553-6610
Travis Lacey 312-609-4935
Follow-on Offering
February 2011
Optimer Pharmaceuticals, Inc.
Target Location
North America